Figure S6 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis | Synapse
August 4, 2025
Figure S6 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Key Points
PLT012, a humanized cd36-blocking antibody, shows efficacy in antitumor immunity against liver cancer.
The treatment effectively inhibits both primary and metastatic growth of mc38 colon cancer.
Results indicate significant potential in combating liver metastasis linked to colon cancer.
The findings highlight an innovative approach to enhancing immunotherapy for liver cancer.
Abstract
The evaluation of PLT012's efficacy in inhibiting both primary and metastatic growth of MC38 colon cancer.